Randomized phase III trial comparing pegylated liposomal doxorubicin (PLD) at 50 mg/m² versus 40 mg/m² in patients with platinum-refractory and -resistant ovarian carcinoma: the JGOG 3018 Trial.
Takashi MotohashiAkira YabunoHirofumi MichimaeTetsuro OhishiMiwa NonakaMasashi TakanoShin NishioHiroyuki FujiwaraKeiichi FujiwaraAsumi OkumuraToru SugiyamaTsutomu TabataPublished in: Journal of gynecologic oncology (2020)
UMIN Clinical Trials Registry Identifier: UMIN000003130.